21 September 2020Choice will depend on clinical condition, and should primarily be based on suitability for the patient, rather than safety during breastfeeding. Whilst sodium valproate is…
12 June 2020This updated Medicines Q&A evaluates the limited evidence available on cross-sensitivity between sulfonamide-containing medicines and lists classes of medication that contain a sulfonamide in their…
Medicine Compliance Aid Stability
Capsules 25mg, 50mg, 100mg
A3 · Amber 3 No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from light in a dry place.
2 March 2015
Lactation Safety Information
Suitable alternative antiepileptic
Long half-life increases risk of accumulation in breastfed infants
Significant amounts in breast milk
Very limited published evidence of safety
10 August 2020
DesizonEpilepsy - oral suspension formulation
Development and Regulatory status
Jan 21Available in UK. Price 20mg/ml oral susp, 250ml=£181.90 .
Mar 20Approved by the MHRA for use as monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy, and also as adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above. Will be available as a 20mg/ml oral suspension .
GABA receptor antagonist
Prevalence of active epilepsy is 5-10 cases per 1,000 - but with 5-30% of these misdiagnosed as having epilepsy. The lifetime risk of having a single seizure is 8-10%, and there is a 3% risk of developing epilepsy .
Epilepsy - oral suspension formulation